Non-Small Cell Lung Cancer Coverage from Every Angle

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

In patients with previously treated advanced KRAS-mutant non–small cell lung cancer (NSCLC), adding the MEK inhibitor selumetinib to docetaxel did not improve progression-free survival, according to the findings of the randomized phase III SELECT-1 clinical trial. Pasi A. Jänne, MD, PhD, of the Dana-Farber Cancer Institute, and colleagues reported these results in a recent issue of JAMA. In addition, no significant improvement in overall survival was reported with the combination therapy.

A total of 510 patients with previously treated locally advanced or metastatic disease from 202 sites in 25 countries were included in this double-blind trial. Among these patients, 94% had KRAS codon 12 or 13 mutations, and 91% had adenocarcinoma histology.

The investigators found no significant improvement in progression-free survival with selumetinib plus docetaxel compared with placebo plus docetaxel (median, 3.9 months vs 2.8 months; P=.44). In addition, no significant interactions of treatment by subgroup were noted. The median overall survival was 8.7 months vs 7.9 months, respectively (P=.64).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.